Saxonov Serge: insider trades.
Saxonov Serge reported 11 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 9 sales ($3.9M), across 1 company.
- Transactions
- 11
- Purchases (P)
- 0
- Sales (S)
- 9
- Companies
- 1
- Name as filed
- Saxonov Serge
Companies
| Company | Relationship | Transactions |
|---|---|---|
| 10x Genomics, Inc. (TXG) | Director, Officer · Chief Executive Officer | 11 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-22 | 10x Genomics, Inc. | S | 1,000 | $78.23 | 1,074,249 | Form 4 |
| 2026-09-22 | 10x Genomics, Inc. | S | 9,900 | $81.83 | 1,053,049 | Form 4 |
| 2026-09-22 | 10x Genomics, Inc. | S | 9,300 | $80.9 | 1,062,949 | Form 4 |
| 2026-09-22 | 10x Genomics, Inc. | S | 2,000 | $79.62 | 1,072,249 | Form 4 |
| 2026-09-22 | 10x Genomics, Inc. | S | 2,800 | $82.37 | 1,050,249 | Form 4 |
| 2026-09-01 | 10x Genomics, Inc. | G | 100 | $0 | 1,075,249 | Form 4 |
| 2026-08-26 | 10x Genomics, Inc. | S | 3,500 | $63.02 | 1,082,335 | Form 4 |
| 2026-08-26 | 10x Genomics, Inc. | S | 6,494 | $63.98 | 1,075,841 | Form 4 |
| 2026-08-26 | 10x Genomics, Inc. | S | 492 | $64.75 | 1,075,349 | Form 4 |
| 2026-08-24 | 10x Genomics, Inc. | S | 18,545 | $63.02 | 1,085,835 | Form 4 |
| 2026-08-20 | 10x Genomics, Inc. | G | 4,000 | $0 | 1,104,380 | Form 4 |
Questions
What stock did Saxonov Serge buy or sell?
Saxonov Serge reported 11 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 9 sales ($3.9M), across 1 company.
Is Saxonov Serge the same person as other filers with this name?
This page covers SEC CIK 1786720 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/saxonov-serge-1786720.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.